{
    "nctId": "NCT04549207",
    "briefTitle": "Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer",
    "officialTitle": "A Randomised Trial Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer (REaCT-Hold BMA)",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Castration-resistant Prostate Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 240,
    "primaryOutcomeMeasure": "Health related quality of life scores",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with either radiologically and/or histologically confirmed bone metastases from castrate resistant prostate cancer or breast cancer who are currently receiving BMA\n* Patient has received BMA for 2 or more years counting from the first BMA dose for bone metastases\n* Age 18 years or older\n* Able to provide verbal consent\n\nExclusion Criteria:\n\n* Definite contraindication for BMA\n* History of, or current evidence of osteonecrosis of the jaw\n* Radiotherapy or surgery to the bone planned within 4 weeks after randomization\n* Current hypercalcemia defined as corrected serum calcium of \\> 3 mmol/L (from standard bloodwork completed within one month prior to treatment dose)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}